New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:21 EDTINSYInsys Therapeutics to advance development of CBD to treat epilepsy
Insys Therapeutics announced plans to advance development of its pharmaceutical Cannabidiol, or CBD, a synthetically produced and over 99% pure form of cannabidiol, to treat epilepsy in children and adults. Insys has engaged a large international Clinical Research Organization to provide development and regulatory services and has hired Mark Davis as Senior Clinical Director to oversee this program. Insys plans to file an Investigational New Drug application with the FDA in the second half of 2014 for CBD for the treatment of epilepsy. In pediatrics, Insys plans to pursue development of treatments for Lennox-Gastaut Syndrome and Dravet Syndrome, which are orphan indications.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
08:30 EDTINSYInsys Therapeutics price target raised to $65 from $57 at RBC Capital
Subscribe for More Information
March 3, 2015
07:09 EDTINSYInsys Therapeutics reports Q4 adjusted EPS 53c, consensus 44c
Reports Q4 revenue $66.5M, consensus $63.45M.
February 26, 2015
07:20 EDTINSYInsys Therapeutics cannabidiol receives fast track designation From FDA
Subscribe for More Information
February 24, 2015
07:07 EDTINSYInsys Therapeutics in-licenses novel mast cell therapy for chronic pelvic pain
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use